Eu2P - European programme in Pharmacovigilance and Pharmacoepidemiology

What Eu2P - European programme in Pharmacovigilance and Pharmacoepidemiology does

Eu2P (founded 2009, headquartered at Université de Bordeaux, France) is the first European training programme in pharmacovigilance and pharmacoepidemiology, structured as an academic consortium of 7 European universities, regulatory agencies (EMA, Dutch Medicines Evaluation Board), and 15+ pharmaceutical companies including AstraZeneca, GSK, Roche, Novartis, and Pfizer. The University of Bordeaux hosts the central office and signs and issues all Eu2P certificates and Master diplomas on behalf of the consortium.

The platform delivers online training through an eLearning management system covering seven course domains — basics of PV and pharmacoepidemiology, benefit assessment of medicines, pharmacovigilance regulations, risk identification and quantification, benefit-risk assessment, medicines and public health, and risk communication. The product portfolio comprises four credential tiers: Short Courses (120–240 minutes, €200–400, self-serve enrolment), Certificates (3–6 ECTS credits, €1,500–€5,000), a two-year Master of Science (€7,000/year student, €12,000/year professional, 120 ECTS with specialisation tracks in Year 2), and a PhD programme. A sub-brand, Am2P, co-developed with NASoP, extends the catalogue into US-focused pharmacovigilance training. Courses are delivered entirely online with flexible modular formats.

Revenue is generated through tuition and fees across the four credential tiers, a €25 application fee, and customised corporate training packages sold to pharma companies, CROs, and regulatory agencies. Tiered pricing offers partner-discounted rates (–40% short courses, –30% certificates, –20% Master) for students and employees of consortium partner institutions. Distribution is direct-to-consumer via the eu2p.org website and "My Eu2P" portal, augmented by consortium-partner referrals and a corporate sales motion. The core operating team is small (9 employees), with most instructional capacity contributed by partner faculty across the consortium.

Name

Eu2P - European programme in Pharmacovigilance and Pharmacoepidemiology

Legal name

Eu2P - European programme in Pharmacovigilance and Pharmacoepidemiology

Website

https://eu2p.org

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Eu2P is a European academic consortium, anchored at the University of Bordeaux, that delivers online training in pharmacovigilance and pharmacoepidemiology to students, healthcare professionals, regulators, and pharmaceutical companies through a multi-tier credential portfolio.

Ownership category

akta.pro rank

Product category

Pharmacovigilance and Pharmacoepidemiology Education

NAICS

Professional and Management Development Training (611430), Colleges, Universities, and Professional Schools (611310), Educational Support Services (61171), Technical and Trade Schools (6115)

SIC

Services-Educational Services (8200)

akta.pro industry

PRIMARYEDABALAU

Pharmaceuticals & Biotechnology

Education/Corporate Training & Professional Development/Industry-Specific Professional Training (e.g., Healthcare, Manufacturing, Construction)

Keywords

• Pharmacovigilance training
• Pharmacoepidemiology education
• Drug safety courses
• Online regulatory training
• Consortium academic programme

Headquarters

HQ city

Bordeaux

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Tuition Fees - Certificate Programmes: Revenue from certificate programmes in pharmacovigilance and pharmacoepidemiology. Certificate fees vary by programme with discounts for Eu2P partner institutions (students and employees receive 30% reduction).
2. Master Programme Fees: Two-year Master of Science programme with separate Year 1 and Year 2 fees. Student rate: 7,000€ per year; Professional rate: 12,000€ per year. Part of a consortium delivering joint degrees.
3. Short Course Fees: Individual short course enrollments priced between 200€ and 400€ per course. Short courses provide certificates of achievement and can be bundled into training packages for corporate clients.
4. Application Fees: 25.00 Euros charged for processing certificate and programme applications through the online registration system.
5. Corporate Training Packages: Customized training packages offered to pharmaceutical companies and agencies for employee development, with special pricing and adapted programmes for organizational needs.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

Eu2P delivers fully online, modular training programmes in pharmacovigilance and pharmacoepidemiology through an academic consortium of 7 European universities, regulatory agencies, and pharmaceutical companies. Its product portfolio spans individual Short Courses (€200-400), ECTS-bearing Certificates, a two-year Master of Science (120 ECTS), and a PhD programme, all structured around seven course domains covering drug safety, regulatory affairs, benefit-risk assessment, and risk communication. A North American sub-brand (Am2P) extends the offering to US-focused pharmacovigilance training, while customized corporate training packages are sold to pharmaceutical companies and CROs.

Product overview

Eu2P is an online education platform delivering a comprehensive portfolio of pharmacovigilance and pharmacoepidemiology training programmes. The offering comprises four credential tiers: Short Courses (standalone 120-240 minute modules priced at €200-400), Certificates (3-6 ECTS credit modules with joint university recognition), a two-year Master of Science (120 ECTS combining Year 1 foundational coursework with Year 2 specialization tracks), and a PhD programme. Additionally, the American Programme in Pharmacovigilance (Am2P) provides North American-specific training. All programmes are delivered entirely online through eLearning, organized across seven course domains covering basics, benefit assessment, regulatory aspects, risk identification/quantification, benefit-risk assessment, public health, and risk communication. Training content is developed by a consortium of universities, regulatory agencies, and pharmaceutical companies, with joint awards from Academic Partners including Université de Bordeaux, Erasmus Universitair Medisch Centrum, and others.

Differentiator

Problem solved

Functional benefit

Brands

• Am2P: American Program in Pharmacovigilance - created by Eu2P and NASoP (North American Chapter of ISoP) for North American pharmacovigilance courses

Products and services

• Short Courses Individual online courses in pharmacovigilance and pharmacoepidemiology that can be taken anytime, ranging from 120 to 240 minutes in duration, priced between €200 and €400, delivering a Certificate of Achievement upon completion of a randomized multiple-choice exam with minimum 80% score. Available in multiple languages including English and Spanish. Suitable for self-directed learners and professionals seeking targeted upskilling.
• Certificates Academic certificate programmes offering 3 or 6 ECTS credits, jointly awarded by Eu2P academic partners, covering specific topics in pharmacovigilance and pharmacoepidemiology with module-based learning and assessments. Student rate: €1,500-€2,500 per certificate; Professional rate: €3,000-€5,000 per certificate. Partner institution discounts of 30% apply.
• Master in Pharmacovigilance and Pharmacoepidemiology Two-year Master of Science degree (120 ECTS credits total) jointly awarded by European universities, consisting of theoretical training (course modules) and practical training (research project). Year 1 includes foundational modules; Year 2 offers specialization tracks. Student rate: €7,000 per year; Professional rate: €12,000 per year. Full-time or part-time options available.
• PhD Programme in Pharmacovigilance and Pharmacoepidemiology Doctoral programme in pharmacovigilance and pharmacoepidemiology for advanced research and academic pursuit. Limited grants available for selected PhD applicants.
• American Programme in Pharmacovigilance (Am2P) North American-focused pharmacovigilance training designed and delivered by the North American Chapter of ISoP (NASoP) and Eu2P, covering US-EU regulatory comparisons, FDA requirements, and US-specific PV practices. Includes both Short Courses and Certificates formats.
• Companies Offer (Corporate Training Packages) Customized training packages offered to pharmaceutical companies, Contract Research Organizations (CROs), and healthcare companies for employee development, with special pricing and adapted programmes tailored to organizational needs in drug safety, regulatory affairs, and pharmacovigilance roles.

Quantifiable outcome

• Joint Master degrees awarded by multiple European universities recognized by all consortium partners including pharmaceutical companies and regulatory agencies
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

19 partnerships are on record, tiered core.

• Université de BordeauxcoreStrategic or Co-development PartnerLead academic partner hosting Eu2P Central Office. Coordinates consortium activities, issues joint certificates and Master diplomas. Université de Bordeaux signs and issues all Eu2P certificates and Master degrees on behalf of the consortium. Coordinates course development and delivery across programme domains.
• Erasmus Universitair Medisch Centrum (Netherlands)coreStrategic or Co-development PartnerAcademic partner contributing to pharmacovigilance and pharmacoepidemiology curriculum. Hosts domain coordinators for risk identification and quantification modules. Contributes faculty expertise in pharmacoepidemiology research and education.
• Universitat Autònoma de Barcelona (Spain)coreStrategic or Co-development PartnerAcademic partner delivering drug utilisation and prescribing pattern analysis modules. Contributes expertise in clinical pharmacology and therapeutic evaluation through faculty like Prof Joan-Ramon Laporte.
• University of Hertfordshire (United Kingdom)coreStrategic or Co-development PartnerAcademic partner coordinating pharmacovigilance regulatory aspects domain. Provides expertise in GVP compliance, pharmacovigilance auditing, and regulatory frameworks through faculty like Sue Rees and Dr Sherael Webley.
• Universiteit Utrecht (Netherlands)coreStrategic or Co-development PartnerAcademic partner contributing benefit-risk assessment and health economics modules. Coordinates advanced analytics for regulatory decisions and health outcomes evaluation programmes.
• Università degli Studi della Campania Luigi Vanvitelli (Italy)coreStrategic or Co-development PartnerAcademic partner delivering risk communication modules. Coordinates effective communication of benefit-risk information through Prof Annalisa Capuano and contributes to medicines risk communication domain.
• University Medical Center Utrecht (Netherlands)coreStrategic or Co-development PartnerAcademic partner contributing quantitative risk assessment and pharmacoepidemiology modules. Hosts Prof Miriam Sturkenboom as coordinator for risk quantification and benefit-risk modeling courses.
• AstraZeneca ABcoreStrategic or Co-development PartnerIndustry partner contributing experts to training content and delivery across multiple modules. Provides practical industry perspectives on pharmacovigilance operations, regulatory compliance, and risk management. Experts include Dr James Whitehead, Dr Jane Feron, and others.
• GlaxoSmithKline Research and Development LtdcoreStrategic or Co-development PartnerIndustry partner providing expert faculty for multiple programme modules including pharmacovigilance regulations, clinical pharmacology, and regulatory affairs. Contributors include Dr Jens-Ulrich Stegmann, Subhash Mistry, and others.
• F. Hoffmann-La Roche LtdcoreStrategic or Co-development PartnerIndustry partner contributing to signal detection, drug utilisation, and clinical pharmacology modules. Expert contributors include Noah Jamie Robinson, Dr James Stevens, and Dr Susan Duke.
• Novartis Pharma AGcoreStrategic or Co-development PartnerIndustry partner providing expertise in pharmacovigilance processes, drug safety management, and regulatory submissions. Contributors include Dr David Lewis and Dr Marion Mueller.
• PfizercoreStrategic or Co-development PartnerIndustry partner contributing to pharmacovigilance auditing, risk management, and regulatory compliance modules. Expert contributors include Helen Robinson, Dr Lubna Merchant, and others.
• European Medicines Agency (EMA)coreStrategic or Co-development PartnerRegulatory partner contributing to pharmacovigilance curriculum. Provides insight into regulatory requirements, signal management, and post-authorization safety studies through expert contributions.
• Dutch Medicines Evaluation BoardcoreStrategic or Co-development PartnerRegulatory partner contributing to signal detection, benefit-risk assessment, and risk communication modules. Expert contributors include Dr Sabine Straus and Dr Peter Mol.
• UCB Pharma SAcoreStrategic or Co-development PartnerIndustry partner contributing to signal detection and pharmacoepidemiology modules. Expert contributors include Dirk Teuwen and Dr Peter Verdru.
• Janssen Pharmaceutica NVcoreStrategic or Co-development PartnerIndustry partner contributing to adverse event management and pharmacoepidemiology study design modules. Expert contributor Dr Martijn Schuemie provides statistical expertise.
• Sanofi-aventis Recherche et DéveloppementcoreStrategic or Co-development PartnerIndustry partner contributing to signal detection and adverse event management modules. Expert contributor Dr Juhaeri provides pharmacoepidemiology expertise.
• Amgen NVcoreStrategic or Co-development PartnerIndustry partner contributing to clinical pharmacology and drug utilisation modules. Expert contributor Janice Fuller provides expertise in therapeutic evaluation.
• ISoP (International Society of Pharmacovigilance) / NASoPcoreStrategic or Co-development PartnerProfessional society partnership enabling North American programme (Am2P) in pharmacovigilance. NASoP (North American Chapter of ISoP) co-develops courses with Eu2P for US market training needs.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Eu2P
• YouTubeyoutube.com/user/eu2p
• Facebookfacebook.com/Eu2P.org
• LinkedInlinkedin.com/company/eu2p-european-programme-in-pharmacovigilance-and-pharmacoepidemiology

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eu2P - European programme in Pharmacovigilance and Pharmacoepidemiology